کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2085333 1545360 2012 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Metabolic monosaccharides altered cell responses to anticancer drugs
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی بیوتکنولوژی یا زیست‌فناوری
پیش نمایش صفحه اول مقاله
Metabolic monosaccharides altered cell responses to anticancer drugs
چکیده انگلیسی

Metabolic glycoengineering has been used to manipulate the glycochemistry of cell surfaces and thus the cell/cell interaction, cell adhesion, and cell migration. However, potential application of glycoengineering in pharmaceutical sciences has not been studied until recently. Here, we reported that Ac4ManNAc, an analog of N-acetyl-d-mannosamine (ManNAc), could affect cell responses to anticancer drugs. Although cells from different tissues and organs responded to Ac4ManNAc treatment differently, treated cells with increased sialic acid contents showed dramatically reduced sensitivity (up to 130 times) to anti-cancer drugs as tested on various drugs with distinct chemical structures and acting mechanisms. Neither increased P-glycoprotein activity nor decreased drug uptake was observed during the course of Ac4ManNAc treatment. However, greatly altered intracellular drug distributions were observed. Most intracellular daunorubicin was found in the perinuclear region, but not the expected nuclei in the Ac4ManNAc treated cells. Since sialoglycoproteins and gangliosides were synthesized in the Golgi, intracellular glycans affected intracellular signal transduction and drug distributions seem to be the main reason for Ac4ManNAc affected cell sensitivity to anticancer drugs. It was interesting to find that although Ac4ManNAc treated breast cancer cells (MDA-MB-231) maintained the same sensitivity to 5-Fluorouracil, the IC50 value of 5-Fluorouracil to the same Ac4ManNAc treated normal cells (MCF-10A) was increased by more than 20 times. Thus, this Ac4ManNAc treatment enlarged drug response difference between normal and tumor cells provides a unique opportunity to further improve the selectivity and therapeutic efficiency of anticancer drugs.

When normal (MCF-10A) and cancer (MDA-MB-231) breast cells were treated with Ac4ManNAc, an analog of N-acetyl-D-mannosamine (ManNAc), the selectivity of anticancer drug 5-Fluorouracil could be increased by more than 20 times.Figure optionsDownload high-quality image (89 K)Download as PowerPoint slide

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Pharmaceutics and Biopharmaceutics - Volume 81, Issue 2, June 2012, Pages 339–345
نویسندگان
, ,